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Abstract
Polymer-coated liposomes can act as versatile drug-delivery systems due to long vascular circulation time and passive targeting by leaky
blood vessels in diseased tissue. We present an experimental model system illustrating a new principle for improved and programmable drug-
delivery, which takes advantage of an elevated activity of secretory phospholipase A2 (PLA2) at the diseased target tissue. The secretory
PLA2 hydrolyses a lipid-based proenhancer in the carrier liposome, producing lyso-phospholipids and free fatty acids, which are shown in a
synergistic way to lead to enhanced liposome destabilization and drug release at the same time as the permeability of the target membrane is
enhanced. Moreover, the proposed system can be made thermosensitive and offers a rational way for developing smart liposome-based drug
delivery systems. This can be achieved by incorporating specific lipid-based proenhancers or prodestabilisers into the liposome carrier, which
automatically becomes activated by PLA2 only at the diseased target sites, such as inflamed or cancerous tissue.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Drug-delivery systems based on liposomal carriers in the
100-nm range [1,2] are one of the modern microcarrier
therapeutic systems that holds a promise for coming close to
realising Paul Erlich’s early vision of a ‘magic bullet’ for
treatment of diseases [3]. Liposomes made of biocompat-
ible, nontoxic phospholipids provide a system for efficient
formulation and encapsulation of toxic drugs that can
effectively evade the immune system [4]. The drug assumes
the altered pharmacokinetics of the liposomal carrier and
can in principle be targeted to the diseased tissue by using a
combination of physicochemical and pathophysiological
factors at the sites of the liposome carrier and the target
membrane, respectively. Liposomes incorporated with lip-
opolymers, such as polyethylene glycol (PEG)-lipids,
known as ‘Stealth’ liposomes [1], display an improved
stability in the vascular system, possibly due to steric
protection caused by the polymer coating. The prolonged
circulation time of these liposomes, combined with in-
creased vascular porosity of diseased tissue [5], has formed
the basis for positive clinical results for specific systems,
including anticancer drugs like doxorubicin [6] as well as
antibacterial [7] and anti-inflammatory [8] drugs.
Liposomes are self-assembled lipid systems and their
stability is therefore, to a large extent, controlled by non-
specific physical interactions. Insight into the molecular
control of the physical properties of liposomes is therefore
important for manipulating and tailoring the liposomal
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properties in relation to specific drug-delivery purposes. As
an example, the thermally induced gel–fluid lipid transition
has been exploited [9] and optimized [10] to design systems
for enhanced release of drugs due to hyperthermia. Re-
cently, it has been suggested that specific peptide-linked
lipids incorporated into the carrier liposome can be turned
into fusogenic agents by the action of proteases in the
tumour thereby promoting the intracellular drug transport
[11]. It would be desirable if an intelligent and versatile
drug-delivery system could be designed which has built in a
dual virtual trigger mechanism of simultaneous (i) enhanced
drug release selectively at the target tissue and (ii) enhanced
transport of the drug into the diseased cells.
In the present study, we propose a new principle for
liposomal targeting to diseased regions that assumes ele-
vated activity of secreted phospholipase A2 (PLA2) at the
diseased sites as is the case in inflamed [12–16] and
cancerous tissue where the level of secretory PLA2 are often
enhanced manyfold over normal levels [17–20]. Upon
exposure to PLA2, the phospholipids of the PEG-liposomes
have been shown to suffer enhanced hydrolysis compared to
conventional bare liposomes [21,22]. This leads to destabi-
lisation of the PEG-liposome and enhanced release of the
encapsulated drug. The hydrolysis products, lyso-phospho-
lipids and free fatty acids, act in turn as absorption en-
hancers for drug permeation across the target membrane.
Fig. 1. (a) Schematic illustration of the new liposomal drug-targeting principle involving accumulation of liposomal drug carriers in porous diseased tissue and
subsequent drug release and transport across the target membrane via endogenous PLA2 activity. (b) Schematic illustration of a molecular-based biophysical
model system where the phospholipids of the carrier liposome, via the PLA2-catalysed hydrolysis, act as prodestabilisers at the site of the carrier and as
proenhancers at the site of the target.
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The phospholipids of the carrier liposome thereby behave as
prodestabilisers at the site of the carrier and as proenhancers
at the site of the target membrane. The new principle for
localized liposomal drug release and absorption that is based
on elevated levels of PLA2 in the diseased tissue is illus-
trated schematically in Fig. 1a.
In order to substantiate and support the novel idea of
localized liposomal drug release and absorption by means
of elevated levels of PLA2, we have developed a simple
and operative experimental biophysical model system that
sustains such a dual mechanism to be triggered at the
pathological target sites. The experimental model system
consists of a polymer-coated liposome carrier and a model
target membrane. Molecular details of the experimental
model system are illustrated schematically in Fig. 1b. The
carrier is a 100-nm unilamellar liposome made of 1,2-
hexadecanoyl-sn-glycero-3-phosphocholine (DPPC) lipids
incorporated with 1,2-hexadecanoyl-sn-glycero-3-phos-
phoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(DPPE-PEG2000). The target membrane is another lipo-
some made of 1,2-O-octadecyl-sn-glycero-3-phosphocho-
line (1,2-di-O-SPC), which is a phospholipid where the
acyl linkages of the stearoyl chains are ether bonds. In
contrast to DPPC, 1,2-di-O-SPC is inert towards PLA2-
catalysed hydrolysis thereby mimicking the stability of a
target cell membrane towards degradation by its own en-
zymes. This experimental assay, which permits simultane-
ous as well as separate investigation of the effect of
destabilisers at the carrier liposomes and the effect of en-
hancers at the target membrane, involves entrapment of a
water-soluble fluorescent calcein model drug, in a self-
quenching concentration, in the interior of the nonhydrolys-
able target liposome, rather than in the carrier liposome. The
enhanced level of PLA2 at the target membrane can then be
simulated by adding PLA2 to initiate the hydrolytic reaction
in a suspension of the carrier and target liposomes. The
permeation of calcein across the 1,2-di-O-SPC target mem-
brane is subsequently monitored by the increase in fluores-
cence. In order to investigate the effect of the presence of the
PEG-lipids in the carrier liposome, a similar experiment was
performed with conventional bare DPPC liposomes. Fur-
thermore, in order to compare and discriminate the perme-
ability-enhancing effect of lyso-phospholipids from that of
free fatty acids, experiments without enzymes were carried
out where 1-hexadecanoyl-2-hydroxy-sn-glycero-3-phos-
phocholine (lysoPPC) and palmitic acid (PA) were added
simultaneously or separately to the target liposomes.
2. Materials and methods
2.1. Materials
The lipids, 1,2-di-O-SPC,DPPC, 1,2-capryl-sn-glycero-3-
phosphocholine (DCPC) and 1,2-hexadecanoyl-sn-glycero-
3-phosphoethanolamine-N-[methoxy(polyethylene glycol)
2000] (DPPE-PEG2000), 1,2-hexadecanoyl-sn-glycero-3-
phosphoethanolamine N-[methoxy(polyethylene glycol)-
350] (DPPE-PEG350), lysoPPC and PA were purchased
from Avanti Polar Lipids (Alabaster, AL). 1-O-hexadecyl-
2-hexadecanoyl-sn-glycero-3-phosphocholine (1-O-DPPC)
and 1-O-hexadecyl-2-hexadecanoyl-sn-glycero-3-phospho-
ethanolamine-N-[methoxy(polyethylene glycol)-350] (1-O-
DPPE-PEG350) were synthesized in our laboratory. PLA2
hydrolysis of the 1-O-DPPC and 1-O-DPPE-PEG350 mo-
noether lipids leads to the release of etherlysolipids, which
are nondegradable by, e.g. lysophospholipases rendering
the generated lysolipid permeability enhancers more stable
in biological fluids. Calcein (2,4-bis-(N,NV-di(carboxyme-
thyl)aminomethyl)-fluorescin) was purchased from ICN
Biochemicals (Costa Mesa, CA) and Sephadex G-50 was
purchased from Pharmacia (Uppsala, Sweden). 1,2-bis-(1-
pyrene-decanoyl)-sn-glycero-3-phosphocholine (bis-py-
DPC) was from Molecular Probes (Eugene, OR). All che-
micals were used without further purification. Purified
snake venom PLA2 (Agkistrodon piscivorus piscivorus)
[23] was a generous gift from Dr. R.L. Biltonen. This
PLA2 enzyme belongs to the class of low molecular weight,
14 kDa secretory enzymes that display structural similarity
to human secretory PLA2 [24–26].
2.2. Preparation of target liposomes containing entrapped
calcein
Multilamellar (MLV) target liposomes were made by
dispersing a weighed amount of lipid in a HEPES buffer
solution (10 mM HEPES, 110 mM KCl, 1 mM NaN3, 30
AM CaCl2, 10 AM NaEDTA, pH 7.5) containing the
water-soluble marker, calcein, in a self-quenching concen-
tration (20 mM). Calcein was dissolved in water and pH
were adjusted with NaOH to pH = 7.5 prior to adding the
calcein solution to the 10 mM HEPES buffer. The lipid
suspension was kept at a temperature 10 jC above the
main phase transition temperature of 1,2-di-O-SPC (Tm =
55.5 jC) for 1 h in order to ensure complete hydration.
During this period, the lipid suspension was vortexed
every 15 min. The multilamellar liposomes were extruded
10 times through two stacked 100 nm pore size polycar-
bonate filters forming large unilamellar liposomes (LUV)
with a narrow size distribution [27]. Untrapped calcein
was removed from the liposome suspension by gel filtra-
tion through a column packed with Sephadex G-50 using
a HEPES buffer solution (10 mM HEPES, 150 mM KCl,
1 mM NaN3, 30 AM CaCl2, 10 AM NaEDTA, pH 7.5) as
eluent. The lipid concentration was determined by HPLC,
and the samples were diluted with eluent to the final lipid
concentration ensuring a calcein concentration of less than
1 AM after release of all the calcein from the liposomes.
Our standard curve for calcein showed that the fluores-
cence intensity of calcein displays a linear dependency on
concentrations up to 1 AM. The high concentration (20
mM) of the encapsulated calcein led to self-quenching of
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its fluorescence, resulting in low background fluorescence
intensity from the liposomes. Control experiments showed
that the calcein fluorescence was unaffected by the pres-
ence of PA and lysoPPC at concentrations used in the
experiments.
2.3. Preparation of carrier liposomes
Weighed amounts of lipids were dissolved in chloro-
form. The solvent was removed by a gentle stream of N2.
The lipid films were then dried overnight under low pres-
sure to remove trace amounts of solvent. Multilamellar
vesicles were made by dispersing the dried lipids in a
buffer solution containing: 150 mM KCl, 10 mM HEPES,
1 mM NaN3, 30 AM CaCl2 and 10 AM EDTA, pH = 7.5.
The multilamellar vesicles were extruded 10 times through
two stacked 100 nm pore size polycarbonate filters as des-
cribed above.
2.4. Calcein release measurements
The permeability-enhancing effect of PLA2-catalysed
hydrolysis products were measured by incubating 100
nm unilamellar carrier liposomes composed of DPPC
incorporated with DPPE-PEG2000 or DCPC, together with
calcein-containing target liposomes in a HEPES buffer
with pH = 7.5 at 37 jC. The snake venom PLA2 (A.
piscivorus piscivorus) was added at time t = 0 in order to
initiate the hydrolytic reaction. As calcein is released from
the 1,2-di-O-SPC target liposomes, a linear increase in the
fluorescence at 520 nm after excitation at 492 nm is
observed when calcein is diluted into the surrounding
buffer. Fluorescence was measured using a SLM DMX-
1100 spectrofluorometer. The time-dependent release of
calcein from the 1,2-di-O-SPC target liposomes was calcu-
lated as: %R(t) = 100 (IF(t) IB)/(Itot IB), where IF(t) is the
measured fluorescence at time t after addition of the
enzyme, IB is the background fluorescence, and Itot is total
fluorescence, measured after addition of Triton X-100 and
complete release of calcein.
In order to discriminate the permeability-enhancing
effect of lysoPPC from that of PA, experiments were
carried out where lysoPPC and PA were added separately
and as an equimolar mixture to the 1,2-di-O-SPC target
liposomes. The permeability enhancers were added to the
target liposomes under vigorous stirring to obtain final
global concentrations of 10.0 AM corresponding to 50.0
mol% of the 1,2-di-O-SPC concentration. LysoPPC was
added directly from a 1 mM aqueous stock solution
containing 20% methanol, and PA was added from a 5
mM 100% methanol stock solution. The equimolar mixture
was added from a 1 mM 20% methanol stock solution. The
final concentration of methanol in the experimental samples
did not exceed 1% (v/v). Control experiments showed that
methanol by itself did not cause any significant calcein
release.
2.5. PLA2 from rat peritoneal inflammatory exudate
Cell-free peritoneal fluid from rat with casein-induced
acute inflammation was prepared by injecting 5 ml 1%
sodium caseinate into the peritoneal cavity of a SPRD male
rat weighing 250–260 g. The rat was sacrificed after 24 h
and the inflammatory fluid was collected from the perito-
neum and centrifuged at 1500 g for 20 min in order to
obtain a cell-free peritoneal fluid [28].
2.6. PLA2 bis-py-DPC assay
Unilamellar liposomes with a narrow size distribution
were prepared from 89 mol% DPPC, 10 mol% DPPE-
PEG350 and 1 mol% bis-py-DPC. Bis-py-DPC is a PLA2
substrate with two adjacent pyrene fluorophores that form
dimers (excimers) emitting at 470 nm upon excitation at
342 nm. PLA2 catalysed lipid hydrolysis separates the two
fluorophores resulting in an increased monomer emission
at 380 nm [29].
3. Results and discussion
3.1. Triggered liposomal release and absorption by PLA2
The results in Fig. 2a show the release of calcein as a
function of time after adding PLA2 to the system. The
reaction time course of the particular PLA2 used has a
characteristic lag-burst behavior with a so-called lag time,
which can be used conveniently as a measure of the
enzymatic activity [30]. A dramatic decrease in the lag time
and a concomitant enhancement of the rate of release are
observed when the carrier liposomes contain the lipopoly-
mers, DPPE-PEG2000, in accordance with previous findings
of enhanced PLA2 degradation of polymer-coated liposomes
[21,22]. The calcein release results suggest that the products
of the PLA2-catalysed hydrolysis of the DPPC lipids of the
carrier, lysoPPC and PA, which are produced in a 1:1 ratio,
are incorporated into the target membrane [31], leading to a
large increase in membrane permeability. These products,
which have very low water solubility, are known, due to
their noncylindrical molecular shapes, to induce a curvature
stress field in the membrane [24,32] or small-scale lateral
phase separation [23], which induce membrane defects and
increased permeability. This is substantiated by the data in
Fig. 3 which show that the addition of lyso-phospholipid or
fatty acid separately to the present target system, in the
absence of PLA2, leads to an increased rate of calcein
release across the target membrane. However, the crucial
effect is that if lysoPPC and PA are added simultaneously in
a 1:1 mixture, a dramatic enhancement in the rate of release
is observed as shown in Fig. 3 [33]. This strongly suggests
that the two enhancers act in a synergistic fashion, thereby
highlighting the unique possibility in exploiting PLA2-
catalysed hydrolysis for combined destabilisation of the
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carrier liposome and enhancement of drug transport across
the target membrane. The synergistic effect is further aug-
mented by the fact that PLA2 is activated by its own
hydrolysis products [23,32], revealing the degradable phos-
pholipids of the carrier liposome as a kind of proactivators.
It should be pointed out that the effect in the present
drug-delivery model system of using lipids as proenhancers
and prodestabilisers via PLA2 activity is dynamic and refers
to an intrinsic time scale. This time scale is the effective
retention time of the carrier liposomes near the target
membrane. The more rapidly the enzyme is activated, the
faster is the drug release and the larger the drug absorption
during the time which the carrier spends near the target.
Furthermore, the faster the enzyme works, the more readily
it becomes available for hydrolysis of other drug-carrying
liposomes that approach the diseased target site.
Once it has been established that PLA2 activity can be
used to control drug release, several rational ways open up
for intelligent improvements of the proposed drug-delivery
system via use of well-known mechanisms of altering PLA2
activity by manipulating the physical properties of the lipid
bilayer [30,34]. Hence the strategy is to modify certain
physical properties of the carrier liposomes without signifi-
cantly changing their vascular circulation time. We shall
illustrate this general principle by demonstrating the effects
of both a physicochemical factor, the lipid composition of
the carrier, and an environmental (thermodynamic) factor,
the local temperature at the target site.
3.2. Effect of lipid composition on liposomal release and
absorption by PLA2
Short-chain phospholipids, such as DCPC are known to
activate PLA2 [35]. The effect on calcein permeation across
the target membranes induced by incorporation of a small
amount of DCPC into the carrier PEG-liposomes is also
shown in Fig. 2a. The release is very fast due to an almost
instantaneous activation of the enzyme. We have furthermore
found that PLA2 becomes deactivated (data not shown) when
a large amount of cholesterol (>20 mol%) is incorporated
into PEG-liposomes. These significant findings are of par-
ticular interest since the blood circulation time of PEG-
liposomes has been reported to be almost the same without
cholesterol as with large amounts of cholesterol [36].
3.3. Effect of temperature on liposomal release and
absorption by PLA2
Temperature is known to have a dramatic and highly
nonlinear effect on PLA2 activation in the region of the gel–
fluid phase transition of saturated phospholipid bilayers
Fig. 3. Total release of calcein across the target membrane 20 min after the
addition of 10 AM PA and lysoPPC, separately, and as an equimolar
mixture. The concentration of the 1,2-di-O-SPC target membranes was 20
AM in a HEPES buffer with pH= 7.5 at a temperature of 39 jC.
Fig. 2. (a) PLA2-controlled release of the fluorescent model drug calcein
across the 1,2-di-O-SPC target membrane as a function of time for different
compositions of the carrier liposome. The temperature is 37 jC. In
comparison with bare DPPC carriers, the rate of release of the model drug is
dramatically enhanced for the polymer-coated carriers, DPPC+ 2.5 mol%
DPPE-PEG2000. A further augmentation of the rate of release is obtained if
the carrier also contains a short-chain phospholipid, DCPC, which acts as a
local activator for the enzyme. (b) PLA2-controlled release of the
fluorescent model drug calcein across the target membrane as a function
of time for different temperatures. As the temperature is raised, the rate of
release is enhanced due to increased activity of the enzyme induced by
structural changes in the lipid bilayer substrate of the carrier liposome,
which consists of DPPC+ 2.5 mol% DPPE-PEG2000. In the present assay, a
maximum release of about 70% is achieved in all cases. The insert shows
the time of 50% calcein release, t50%, as a function of temperature.
J. Davidsen et al. / Biochimica et Biophysica Acta 1609 (2003) 95–101 99
[30,37]. This effect is not caused by changes in the enzyme
but by dramatic lateral structural changes in the lipid bilayer
[38]. It is possible to take advantage of this effect in the
present drug-delivery system as suggested by the data in
Fig. 2b. As the temperature approaches the main phase
transition temperature at 41jC, the rate of calcein release is
progressively enhanced as quantified by the time of 50%
calcein release, t50%, shown in the insert to Fig. 2b. It has
previously been suggested that hypertermia could be ex-
ploited to enhance drug release, and that local heating at
predefined tumour areas could be used to locally destabilise
drug-carrying liposomes, by exploiting the enhanced leaki-
ness of liposomes at their phase transition [9].
3.4. Liposomal release and absorption as a function of
PLA2 concentration
The release of calcein entrapped in carrier liposomes
composed of 1-O-DPPC incorporated with 10 mol% 1-O-
DPPE-PEG350 was measured as a function of enzyme
concentration. The results in Fig. 4 demonstrate that rapid
release, within minutes, can be obtained even at 1 nM PLA2
(f 14 ng/ml). Interestingly, the PLA2 concentrations found
in effusions from patients with various cancer types were in
the range from 9 to 188 ng/ml [17]. It should be noted that
PLA2 is able to hydrolyse the 1-O-DPPC and 1-O-DPPE-
PEG350 monoether lipids leading to the release of lysolipids
that are stable against hydrolysis by, e.g. lysophospholi-
pases. The released etherlysolipids are expected to display
an increased in vivo stability thereby having the potential to
induce a more pronounced permeability enhancing effect in
the diseased tissue.
3.5. Activity of PLA2 from inflammatory exudate
Finally, it was investigated whether DPPC drug carrier
liposomes incorporated with 10 mol% DPPE-PEG350 were
degraded by mammal secretory PLA2 obtained from rat
peritoneum fluid. In Fig. 5, a sudden increase in monomer
fluorescence and a simultaneously decrease in excimer
fluorescence is observed approx. 2200 s after adding rat
peritoneal fluid to the equilibrated suspension, indicating
that bis-py-DPC is hydrolysed by PLA2 originating from the
peritoneal inflammatory fluid [28,29,39]. Interestingly, it
has recently been shown that group V PLA2 and group X
PLA2 are upregulated and secreted by macrophages in
inflammatory tissue [12,16], and that these two enzymes
display a high hydrolyzing activity against zwitterionic
phosphatidylcholine lipids as it is reflected by the results
shown in Fig. 5.
4. Conclusion
Polymer-grafted liposomes are known to accumulate in
diseased tissue with leaky capillaries due to a long vascular
circulation time. The results reported in the present paper
suggest that polymer-grafted liposomal drug carriers can
also be constructed to become susceptible to PLA2 catalysed
degradation in the diseased tissue, which is characterised by
increased levels of PLA2. Through this, it is possible to
achieve a remote and site-specific release and absorption of
the encapsulated drugs specifically at the diseased target
site. This new principle for targeted liposomal drug delivery
to diseased tissue implies that the PLA2 controlled release
will be enhanced where both temperature and PLA2 con-
centration are elevated, e.g. in inflamed tissue, independent
of the size of the diseased region and without requiring a
preceding localisation of the diseased tissue. This is in
contrast with the case where the thermic effect can only
be achieved by a local temperature increase using external
heating sources at a predetermined tumour site of some
minimal size [10].
Fig. 4. PLA2-controlled release of calcein from liposomes composed of 25
AM 90 mol% 1-O-DPPC and 10 mol% 1-O-DPPE-PEG350 suspended in a
10 mM HEPES-buffer (pH= 7.5), as a function of time. Decreasing
concentrations of PLA2 (A. piscivorus piscivorus) was added at time 300 s.
The temperature was 35.5 jC.
Fig. 5. Characteristic reaction time profile at 38.5 jC for rat phospholipase
catalyzed hydrolysis of DPPC liposomes incorporated with 10 mol%
DPPE-PEG350. The catalytic reaction was initiated by adding cell-free
peritoneal fluid at t = 60 s to 2.5 ml of the thermostated liposome
suspension. The hydrolysis reaction is monitored by monomer fluorescence
(solid line) and eximer fluorescence (dashed line) from bis-py-DPC.
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